Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; com… Read more
Longeveron LLC (LGVN) - Net Assets
Latest net assets as of September 2025: $9.97 Million USD
Based on the latest financial reports, Longeveron LLC (LGVN) has net assets worth $9.97 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.56 Million) and total liabilities ($5.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.97 Million |
| % of Total Assets | 64.06% |
| Annual Growth Rate | 21.46% |
| 5-Year Change | 1018.4% |
| 10-Year Change | N/A |
| Growth Volatility | 681.89 |
Longeveron LLC - Net Assets Trend (2018–2024)
This chart illustrates how Longeveron LLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Longeveron LLC (2018–2024)
The table below shows the annual net assets of Longeveron LLC from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $21.89 Million | +224.68% |
| 2023-12-31 | $6.74 Million | -67.12% |
| 2022-12-31 | $20.50 Million | -45.26% |
| 2021-12-31 | $37.45 Million | +1813.80% |
| 2020-12-31 | $1.96 Million | -55.97% |
| 2019-12-31 | $4.45 Million | -34.77% |
| 2018-12-31 | $6.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Longeveron LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10960700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | 0.06% |
| Other Components | $131.48 Million | 600.72% |
| Total Equity | $21.89 Million | 100.00% |
Longeveron LLC Competitors by Market Cap
The table below lists competitors of Longeveron LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zee Learn Limited
NSE:ZEELEARN
|
$14.72 Million |
|
VAIV Co. Inc.
KQ:301300
|
$14.72 Million |
|
EcoBio Holdings Co. Ltd
KQ:038870
|
$14.72 Million |
|
Sentien Printing Factory Co Ltd
TWO:8410
|
$14.72 Million |
|
Sutlej Textiles and Industries Limited
NSE:SUTLEJTEX
|
$14.72 Million |
|
Delta Djakarta Tbk
JK:DLTA
|
$14.71 Million |
|
Murray Cod Australia Ltd
AU:MCA
|
$14.71 Million |
|
PEPTONIC MEDICAL
F:28L
|
$14.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Longeveron LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,741,000 to 21,887,000, a change of 15,146,000 (224.7%).
- Net loss of 15,973,000 reduced equity.
- Dividend payments of 8,650,000 reduced retained earnings.
- New share issuances of 12,866,000 increased equity.
- Other comprehensive income increased equity by 100,000.
- Other factors increased equity by 26,803,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.97 Million | -72.98% |
| Dividends Paid | $8.65 Million | -39.52% |
| Share Issuances | $12.87 Million | +58.78% |
| Other Comprehensive Income | $100.00K | +0.46% |
| Other Changes | $26.80 Million | +122.46% |
| Total Change | $- | 224.68% |
Book Value vs Market Value Analysis
This analysis compares Longeveron LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.22x to 0.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $4.28 | $0.96 | x |
| 2019-12-31 | $2.78 | $0.96 | x |
| 2020-12-31 | $1.16 | $0.96 | x |
| 2021-12-31 | $19.80 | $0.96 | x |
| 2022-12-31 | $9.78 | $0.96 | x |
| 2023-12-31 | $3.10 | $0.96 | x |
| 2024-12-31 | $1.47 | $0.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Longeveron LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -667.77%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.17x
- Recent ROE (-72.98%) is above the historical average (-127.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -92.99% | -296.84% | 0.20x | 1.54x | $-7.02 Million |
| 2019 | -83.71% | -66.09% | 0.53x | 2.38x | $-4.17 Million |
| 2020 | -190.14% | -66.10% | 0.61x | 4.72x | $-3.92 Million |
| 2021 | -45.51% | -1305.13% | 0.03x | 1.14x | $-20.79 Million |
| 2022 | -91.86% | -1541.33% | 0.04x | 1.34x | $-20.89 Million |
| 2023 | -317.65% | -3020.17% | 0.06x | 1.79x | $-22.09 Million |
| 2024 | -72.98% | -667.77% | 0.09x | 1.17x | $-18.16 Million |
Industry Comparison
This section compares Longeveron LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Longeveron LLC (LGVN) | $9.97 Million | -92.99% | 0.56x | $14.72 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |